Who is sponsoring NCT02683200?

NCT02683200 is sponsored by Jonsson Comprehensive Cancer Center.

What drugs are being tested in NCT02683200?

Interventions in NCT02683200: Image-Guided Adaptive Radiation Therapy, Stereotactic Body Radiation Therapy.

What condition does NCT02683200 study?

NCT02683200 studies Adult Hepatocellular Carcinoma, Metastatic Malignant Neoplasm in the Liver.

Is NCT02683200 still recruiting?

NCT02683200 is currently completed. Last updated 21 February 2023.

Last reviewed 2023-02-21 · How we verify

NCT02683200

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

MRI-Guided Stereotactic Body Radiation Therapy in Treating Patients With Liver Metastases or Liver Cancer

Completed EARLY_PHASE1 Last updated 21 February 2023

What this trial tests

EARLY_PHASE1 trial testing Image-Guided Adaptive Radiation Therapy in Adult Hepatocellular Carcinoma in 21 participants. Completed in 1 January 2022.

Timeline

3 June 2015

Primary endpoint
1 January 2022

1 January 2022

Quick facts

Lead sponsor	Jonsson Comprehensive Cancer Center
Phase	EARLY_PHASE1
Status	Completed
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	21
Start date	3 June 2015
Primary completion	1 January 2022
Estimated completion	1 January 2022
Sites	1 location across United States

Drugs / interventions tested

Image-Guided Adaptive Radiation Therapy
Stereotactic Body Radiation Therapy — full drug profile →

Conditions studied

Adult Hepatocellular Carcinoma — all drugs for Adult Hepatocellular Carcinoma →
Metastatic Malignant Neoplasm in the Liver — all drugs for Metastatic Malignant Neoplasm in the Liver →

Sponsor

Jonsson Comprehensive Cancer Center — full company profile →

Who can join

18 and older, any sex, with Adult Hepatocellular Carcinoma or Metastatic Malignant Neoplasm in the Liver. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This pilot clinical trial studies magnetic resonance imaging (MRI)-guided stereotactic body radiation therapy (SBRT) in treating patients with liver metastases or liver cancer. SBRT is a specialized radiation therapy that delivers a single, high dose of radiation directly to the tumor and may kill more tumor cells and cause less damage to normal tissue. Combining MRI with SBRT may help doctors to highlight the tissues surrounding the tumor better.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

MRIgRT head and neck anthropomorphic QA phantom: Design, development, reproducibility, and feasibility study.
Steinmann A, Alvarez P, Lee H, Court L, et al · · 2020 · cited 11× · PMID 31808949 · DOI 10.1002/mp.13951

Verify or expand the search:

Other trials of Image-Guided Adaptive Radiation Therapy

Trials testing the same drug.

NCT06325046 — Adaptive Radiation Therapy (ART) Stereotactic Ablative Body Radiotherapy (SABR) for Primary Localized Prostate Cancer · NA · recruiting
NCT05830838 — Daily Adaptive Post-Prostatectomy With Stereotactic Ablative Radiotherapy in Patients With Prostate Cancer · NA · active not recruiting
NCT01507428 — Study of Positron Emission Tomography and Computed Tomography in Guiding Radiation Therapy in Patients With Stage III No · Phase 2 · unknown

Other recruiting trials for Adult Hepatocellular Carcinoma

Currently open trials in the same condition.

NCT02379377 — 18F-FSPG PET in Imaging Patients With Liver Cancer Before Undergoing Surgery or Transplant · Phase 1 · recruiting

Other Jonsson Comprehensive Cancer Center trials

Trials by the same sponsor.

NCT07229339 — Zipalertinib With Carboplatin and Pemetrexed for the Treatment of Resectable, Stage II-IIIB, Non-Small Cell Lung Cancer · Phase 2 · not yet recruiting
NCT06448286 — PH Weighted Chemical Exchange Saturation Transfer MRI-Based Surgical Resection to Improve Survival in Patients With Glio · Phase 3 · not yet recruiting
NCT07517211 — A Prospective Study of Physical Function in Adults Who Receive Systemic Therapy for Stage I-III Gastroesophageal Cancer, · not yet recruiting
NCT07191717 — Imlunestrant and Abemaciclib for the Treatment of Estrogen Receptor Positive Breast Cancer in Patients With Minimal Resi · Phase 2 · not yet recruiting
NCT07468903 — Focal Radiation Therapy (HDR-Brachytherapy) for the Treatment of Prostate Cancer · NA · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT02683200 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Jonsson Comprehensive Cancer Center
Last refreshed: 21 February 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02683200.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing